Market news
Detailed price information for Larimar Therapeutics Inc (LRMR-Q) from The Globe and Mail including charting and trades.
Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measuresHigh patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion
Larimar Therapeutics Inc. (NASDAQ:LRMR) is one of the 10 best stocks under $10 that could triple. On June 29, Larimar Therapeutics Inc. (NASDAQ:LRMR) filed the first module of its Biologics License Application (BLA) to the U.S. FDA to get its Nomlabofusp therapy approved on an accelerated basis. The company also plans to submit the other […]
The shares were acquired in multiple transactions at prices ranging from $3.33 to $3.35 per share.
Larimar Therapeutics, Inc. (NASDAQ:LRMR) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 19, Samantha Semenkow, an analyst from Citi, maintained a Buy rating on Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a price target of $14. The firm noted that the bullish sentiment is based on the company’s lead drug […]
This is the newest page. Registered accounts read further back.